Jpmorgan Chase & CO Adverum Biotechnologies, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.5 - $2.33 $2,133 - $3,313	-1,422 Reduced 77.83%	405 $0
Q2 2023 Aug 11, 2023	SELL	$0.68 - $1.59 $821,701 - $1.92 Million	-1,208,385 Reduced 99.85%	1,827 $2,000
Q4 2022 Feb 13, 2023	SELL	$0.54 - $10.3 $2,172 - $41,447	-4,024 Reduced 0.33%	1,210,212 $701,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $400,414 - $4.04 Million	-417,098 Reduced 25.57%	1,214,236 $1.15 Million
Q2 2022 Aug 11, 2022	SELL	$0.81 - $1.34 $45,310 - $74,958	-55,939 Reduced 3.32%	1,631,334 $1.96 Million
Q1 2022 May 11, 2022	SELL	$1.23 - $1.95 $459,631 - $728,683	-373,684 Reduced 18.13%	1,687,273 $2.21 Million
Q4 2021 Feb 10, 2022	SELL	$1.74 - $2.4 $357,768 - $493,473	-205,614 Reduced 9.07%	2,060,957 $3.63 Million
Q3 2021 Nov 12, 2021	BUY	$2.08 - $3.6 $4.71 Million - $8.16 Million	2,266,571 New	2,266,571 $4.92 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.